FDA, after turbulent year, leaves drugmakers guessing on its direction

BioPharma Dive

Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator is as unpredictable as it s ever been.

RegulatoryRead full story